Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sirtex Collaboration with the National Cancer Centre of Singapore

Published: Friday, December 07, 2012
Last Updated: Friday, December 07, 2012
Bookmark and Share
Researchers from SGH and NCCS will explore the potential of Carbon Cage Nanoparticles to develop a new generation of cancer therapies.

Sirtex Medical Limited has announced that it has signed a Master Research Collaboration Agreement with SingHealth.

Under this agreement researchers from Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) will explore the potential of a new technology known as Carbon Cage Nanoparticles to develop a new generation of cancer therapies.

Developed by the Australian National University, Carbon Cage Nanoparticles can safely deliver radioactive substances to specific cancer sites deep within the body.

The nanoparticles may even evade detection by patients’ immune systems, improving their ability to target specific cancers.

SingHealth’s team of leading medical scientists and physicians have been quick to recognize these unique properties and the many potential applications of this technology that may represent a breakthrough in the treatment of a range of different cancers.

The master agreement will comprise several research projects. The first will evaluate the technology’s use in the treatment of advanced ovarian cancer that has spread within the abdominal and pelvic cavities.

Ovarian cancer is a common cancer in women and has few or no symptoms in its early stages. As a result, most women are diagnosed late, when the disease has spread and prognosis is poor.

A variety of other gastro-intestinal, hepato-biliary and female genito-urinary cancers may potentially benefit from such a treatment approach.

Mr Gilman Wong, Chief Executive Officer, Sirtex said, “Over the past six years Sirtex has been working with the Australian National University to develop a leading position in nanoparticle IP that may be developed for the treatment of human cancers in areas of unmet clinical need. This Master Research Collaboration Agreement with SingHealth is a milestone in the development of Sirtex’s Carbon Cage Nanoparticle technology and brings together a leading group of physician scientists from the National Cancer Centre of Singapore with a strong track record of transitioning new technologies into the clinic.”

Professor Soo Khee Chee, Deputy Group CEO (Research and Education), SingHealth, and Director, NCCS said “Sirtex’s partnership with SingHealth is a clear testimony of our capability to provide high quality pre-clinical and translational research that can be used to develop new products. Collaborations with industry partners such as Sirtex provide new, cutting-edge technologies that allow us to offer our patients better treatment options, faster.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Smart Patch Releases Blood Thinners When Needed
Researchers have developed a smart patch that activelly monitors a patient's blood and releases blood thinning drugs when necessary.
First-Ever Capsule to Treat Hemophilia
In the near future, hemophiliacs could be able to treat their disease by simply swallowing a capsule.
Enhancing CRISPR to Explore Further
Researchers have developed sOPTiKO, a more efficient and controllable CRISPR genome editing platform.
New Compound to Reduce Tumor Growth
Researchers at Stanford found that a new cell surface receptor they created is effective at inhibiting cancer growth in mice.
Long-Lasting Pill to Fight Malaria
An ultra-long acting pill has been developed to offer a new hope in eliminating malaria.
History of Cells Told Through MEMOIR
MEMOIR technique developed by CalTech researchers enables the life history of cells to be read.
Synthetic Protein Captures DNA Events Leading to Cancer
A team of scientists have developed new technology allowing them to identify molecular intermediates that can drive genetic change.
Precision Medicine for Rheumatoid Arthritis
Researchers identify gene mechanism that increases rheumatoid arthritis risk in susceptable individuals.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!